2:26-cv-11105
Shionogi Inc v. Apotex Inc
I. Executive Summary and Procedural Information
- Parties & Counsel:
- Plaintiff: Shionogi Inc. (Delaware)
- Defendant: Apotex Inc. (Canada) and Apotex Corp.
- Plaintiff's Counsel: FBT Gibbons LLP
- Case Identification: Shionogi Inc. v. Apotex Inc., 2:26-cv-11105, D.N.J., 08/28/2026
- Venue Allegations: Venue is alleged to be proper because Apotex Inc. is a foreign corporation, and Apotex Corp. has a regular and established place of business in New Jersey, has committed acts of infringement there, and has previously consented to venue in the district.
- Core Dispute: Plaintiff alleges that Defendants' filing of an Abbreviated New Drug Application (ANDA) seeking to market a generic version of Plaintiff's RADICAVA ORS® product constitutes infringement of four patents related to oral formulations of edaravone and methods for their administration in treating amyotrophic lateral sclerosis (ALS).
- Technical Context: The technology concerns oral formulations of edaravone, an antioxidant used to treat ALS, designed to provide a more convenient alternative to intravenous administration while managing the drug's interactions with food to ensure consistent therapeutic exposure.
- Key Procedural History: This is a Hatch-Waxman action triggered by Defendants' ANDA filing (No. 219256) with a Paragraph IV certification challenging the patents-in-suit. The complaint notes that RADICAVA ORS® has FDA-granted Orphan Drug Exclusivity expiring May 12, 2029. Plaintiff Shionogi acquired the RADICAVA ORS® business on April 1, 2026. The complaint also references numerous other pending lawsuits against different generic manufacturers concerning the same drug and patents.
Case Timeline
| Date | Event |
|---|---|
| 2018-11-02 | '586 Patent Priority Date |
| 2020-11-12 | '611, '769, and '469 Patent Priority Date |
| 2022-05-12 | FDA grants approval for RADICAVA ORS® (NDA No. 215446) |
| 2024-03-28 | FDA grants Orphan Drug Exclusivity for RADICAVA ORS® |
| 2025-11-25 | '611 Patent Issue Date |
| 2026-01-20 | '769 Patent Issue Date |
| 2026-03-10 | '469 Patent Issue Date |
| 2026-04-01 | Shionogi acquires ownership of RADICAVA ORS® assets |
| 2026-04-14 | '586 Patent Issue Date |
| 2026-07-14 | Shionogi receives Apotex's Notice Letter regarding ANDA No. 219256 |
| 2026-08-28 | Complaint Filing Date |
II. Technology and Patent(s)-in-Suit Analysis
U.S. Patent No. 12,478,611 - "Pharmaceutical composition for oral administration of edaravone and method of administering same"
The Invention Explained
- Problem Addressed: The patent addresses the challenge of oral administration for edaravone, a drug used to treat oxidative stress diseases like ALS, where meal consumption can negatively affect the drug's pharmacokinetics. '611 Patent, col. 3:9-12 '611 Patent, col. 1:26-31
- The Patented Solution: The patent claims a method of administering an oral edaravone composition by specifying time intervals between meal consumption and drug administration that vary based on the meal's fat content (e.g., high-fat, standard, or light meal). '611 Patent, abstract This method is designed to maintain the drug's pharmacokinetic profile (e.g., Cmax and AUC) as if it were administered in a fasted state, thereby avoiding the "food effect." '611 Patent, col. 5:56-6:19 Figures 1 and 3 in the patent provide clinical data plots comparing pharmacokinetic parameters under fasted and various post-meal conditions. '611 Patent, FIG. 1 '611 Patent, FIG. 3
- Technical Importance: This method allows for a predictable therapeutic effect from an oral formulation, which improves quality of life for ALS patients compared to the previously available intravenous infusions. Compl. ¶¶11-12
Key Claims at a Glance
- The complaint asserts at least Independent Claim 1. Compl. ¶49
- Independent Claim 1 of the '611 patent includes the following essential elements:
- A method of treating amyotrophic lateral sclerosis.
- Orally or intragastrically administering a liquid pharmaceutical composition comprising edaravone.
- Administering with a "first time interval" from a meal consumption to the administration.
- The time interval must achieve "the same pharmacokinetics as administration... under a fasting condition of 10 hours or longer."
- The dose of edaravone is in a range of 90 to 120 mg.
- The first time interval is 8 hours for a high-fat meal, 4 hours for a standard meal, and 2 hours for a light meal.
- The complaint does not explicitly reserve the right to assert dependent claims but alleges infringement of "one or more claims." Compl. ¶49
U.S. Patent No. 12,527,769 - "Pharmaceutical composition for oral administration of edaravone and method of administering same"
The Invention Explained
- Problem Addressed: As with the '611 patent, this patent seeks to manage the food effect on the pharmacokinetics of orally administered edaravone for the treatment of ALS. '769 Patent, col. 3:9-12
- The Patented Solution: The patent claims a method of administering a liquid suspension of edaravone at specific time intervals after different meal types. '769 Patent, Claim 1 This method differs from the '611 patent by explicitly claiming a "suspension" and defining the desired pharmacokinetic outcome not as "the same" as a fasted state, but as limiting any potential decrease in Cmax to less than 20% and/or any decrease in AUC to less than 10% relative to a fasted state. '769 Patent, Claim 1
- Technical Importance: This approach provides a defined, quantifiable standard for managing the food effect with an oral suspension, giving practitioners a clear target for achieving consistent drug exposure. Compl. ¶¶11-12
Key Claims at a Glance
- The complaint asserts at least Independent Claim 1. Compl. ¶60
- Independent Claim 1 of the '769 patent includes the following essential elements:
- A method of treating amyotrophic lateral sclerosis.
- Orally or intragastrically administering a liquid pharmaceutical composition that is a "suspension" comprising edaravone.
- Administering with a "first time interval" after a meal.
- The time interval is 8 hours for a high-fat meal, 4 hours for a low-fat meal, or 2 hours for a caloric supplement of 250 calories.
- This administration results in a decrease in Cmax of less than 20% and/or a decrease in AUC of less than 10% compared to administration in a fasted state.
- The complaint alleges infringement of "one or more claims." Compl. ¶60
U.S. Patent No. 12,569,469 - "Pharmaceutical composition for oral administration of edaravone and method of administering same"
Technology Synopsis
The '469 patent claims a method of treating ALS by administering a liquid edaravone composition with specific time intervals relative to different meal types to manage the food effect on drug absorption. '469 Patent, abstract A key feature is the inclusion of a "second time interval" of at least one hour from administration to the consumption of the next meal. '469 Patent, Claim 1
Asserted Claims
At least Independent Claim 1. Compl. ¶71
Accused Features
The administration of Apotex's proposed generic edaravone product as will be instructed by its labeling. Compl. ¶¶70-72
U.S. Patent No. 12,599,586 - "Edaravone suspension for oral administration"
Technology Synopsis
The '586 patent claims a specific formulation for an oral edaravone suspension, rather than a method of use. The invention is an aqueous suspension containing edaravone particles and a dispersant, formulated to achieve certain physical properties (e.g., particle size, dissolution rate) that lead to high bioavailability, comparable to an intravenous injection. '586 Patent, abstract '586 Patent, col. 2:11-44
Asserted Claims
At least Independent Claim 1. Compl. ¶82
Accused Features
The composition of Apotex's proposed generic edaravone suspension product itself. Compl. ¶¶81-82
III. The Accused Instrumentality
Product Identification
The accused instrumentality is Defendants' proposed generic edaravone oral suspension, for which they submitted ANDA No. 219256 to the FDA. (Compl. ¶¶2; Compl. ¶20).
Functionality and Market Context
- The complaint alleges the accused product is a proposed generic copy of Shionogi's RADICAVA ORS®, which is an oral suspension containing edaravone at a dose concentration of 105 mg/5 mL. Compl. ¶9 Compl. ¶42 Compl. ¶44 The product is intended for the treatment of ALS to slow the progression of physical function loss. Compl. ¶11
- The complaint alleges that RADICAVA ORS®, the reference drug, is a significant therapy for ALS, representing a clinically superior oral option compared to the previously available intravenous formulation. (Compl. ¶¶8; Compl. ¶12).
- No probative visual evidence provided in complaint.
IV. Analysis of Infringement Allegations
The complaint does not provide a detailed claim chart or specific factual allegations mapping elements of the accused product to the claim limitations. The infringement theory is based on the allegation that the filing of the ANDA itself is an act of infringement under 35 U.S.C. § 271(e)(2) and that the product, if approved and marketed, will directly and indirectly infringe. Compl. ¶50 Compl. ¶51
U.S. Patent No. 12,478,611 Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A method of treating amyotrophic lateral sclerosis... | The complaint alleges Apotex's ANDA seeks approval to market its product for the treatment of ALS. | ¶42 | col. 12:20-22 |
| ...orally or intragastrically administering... a liquid pharmaceutical composition comprising edaravone... | Apotex's proposed product is alleged to be an oral suspension of edaravone. | ¶42 | col. 4:1-5 |
| ...with a first time interval from a consumption of a meal... wherein the liquid pharmaceutical composition is administered... such that a dose of edaravone per administration is in a range of 90 to 120 mg... | The complaint alleges that Apotex's proposed labeling will instruct administration of its product, which contains 105 mg of edaravone, in a manner that practices the claimed method. | ¶42; ¶50 | col. 12:28-33 |
| ...the first time interval for the consumption of a high-fat meal... is 8 hours before... the first time interval for the consumption of a standard meal... is 4 hours before... and the first time interval for the consumption of a light meal... is 2 hours before... | The complaint alleges Apotex's proposed product labeling will instruct administration according to the claimed time intervals, thereby inducing infringement. | ¶50 | col. 12:33-46 |
| ...such that the first time interval achieves the same pharmacokinetics as administration of the liquid pharmaceutical composition by the same method to the subject under a fasting condition of 10 hours or longer... | The complaint alleges Apotex's product performs substantially the same function to achieve the same result as the claimed method. | ¶49 | col. 12:23-28 |
U.S. Patent No. 12,527,769 Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A method of treating amyotrophic lateral sclerosis... | The complaint alleges Apotex's ANDA seeks approval to market its product for the treatment of ALS. | ¶42 | col. 43:20-21 |
| ...orally or intragastrically administering... a liquid pharmaceutical composition... wherein the liquid pharmaceutical composition is a suspension comprising the edaravone... | Apotex's proposed product is alleged to be an oral suspension of edaravone. | ¶42 | col. 44:60-63 |
| ...the first time interval for the consumption of a high-fat meal... is 8 hours before... the first time interval for the consumption of a low-fat meal... is 4 hours before... or the first time interval for the consumption of a caloric supplement of 250 calories is 2 hours before... | The complaint alleges Apotex's proposed product labeling will instruct administration according to the claimed time intervals, thereby inducing infringement. | ¶61 | col. 45:3-12 |
| ...such that a decrease in Cmax is less than 20% with respect to Cmax in a same time range in fasting for 10 hours or longer and/or that a decrease in AUC is less than 10% with respect to AUC in a same time range in fasting for 10 hours or longer. | The complaint alleges Apotex's product performs substantially the same function to obtain the same result, implying it meets this pharmacokinetic requirement. | ¶60 | col. 45:13-19 |
Identified Points of Contention
- Scope Questions: For the asserted method patents ('611, '769, '469), a central question for induced infringement will be whether the instructions in Apotex's proposed label will direct administration in a way that falls within the specific timing and meal-type limitations of the claims. As the label is not in the complaint, this remains a key open question.
- Technical Questions: The infringement analysis for the '769 patent will raise the evidentiary question of whether Apotex's product, when administered according to its label, actually achieves the claimed pharmacokinetic outcome (e.g., "decrease in Cmax is less than 20%"). Similarly, for the '586 composition patent, the analysis will depend on whether Apotex's formulation literally possesses the claimed ingredients and physical properties. The complaint lacks the specific technical details to analyze these points.
V. Key Claim Terms for Construction
The Term: "the same pharmacokinetics as administration... under a fasting condition" ('611 Patent, Claim 1)
Context and Importance
This term is the central performance standard of Claim 1 of the '611 patent. Its definition is critical because it dictates the evidentiary standard for infringement; a narrow definition could make infringement more difficult to prove.
Intrinsic Evidence for Interpretation
- Evidence for a Broader Interpretation: The specification suggests the term can be interpreted according to established regulatory standards, stating it "indicates statistically the same level to common criteria for bioequivalence (e.g., a least squares mean ratio and its 90% confidence interval are in the range of 0.8 to 1.25)." '611 Patent, col. 6:15-19 This may support an argument that meeting the well-defined bioequivalence standard is sufficient.
- Evidence for a Narrower Interpretation: The specification also uses less precise language, such as "completely identical or in a range not significantly different" and "indicates no significant change." '611 Patent, col. 6:4-10 This language could support an argument for a stricter, more literal comparison of pharmacokinetic parameters than the standard bioequivalence test allows.
The Term: "suspension" '769 Patent, Claim 1
Context and Importance
This term limits Claim 1 of the '769 patent to a specific type of liquid formulation. Infringement will depend on whether Apotex's product is properly classified as a "suspension." Practitioners may focus on this term to determine if there is a definitional mismatch with the accused product.
Intrinsic Evidence for Interpretation
- Evidence for a Broader Interpretation: The patent describes the suspension as including "edaravone particles, a dispersing agent and water" and potentially a "thickening agent." '769 Patent, col. 5:7-12 It provides several detailed examples of such formulations. '769 Patent, col. 13:42-15:18 This may support a broad definition covering any liquid where edaravone particles are dispersed.
- Evidence for a Narrower Interpretation: The patent specification distinguishes between "solutions" and "suspensions," suggesting the terms are mutually exclusive. '769 Patent, col. 4:60-65 An argument could be made that if the accused product is technically a solution (i.e., fully dissolved), it would not meet this limitation.
VI. Other Allegations
Indirect Infringement
The complaint alleges induced infringement under 35 U.S.C. § 271(b) for all asserted patents. The basis for this allegation is that Apotex's proposed product labeling will instruct, encourage, and/or promote administration by physicians and patients in a manner that directly infringes the claimed methods. Compl. ¶50 Compl. ¶61 Compl. ¶72
Willful Infringement
The complaint alleges that Apotex was aware of the patents-in-suit prior to amending its ANDA to include a Paragraph IV certification. Compl. ¶54 Compl. ¶65 Compl. ¶76 Compl. ¶86 It further alleges that Apotex knew of the "objectively high likelihood that its submission constituted infringement of a valid patent," which may support a claim for willful infringement based on pre-suit knowledge. Compl. ¶54
VII. Analyst's Conclusion: Key Questions for the Case
A core issue will be one of evidentiary proof for method claims: Since the complaint lacks the proposed product label, a central question is whether the instructions on Apotex's label will, in fact, direct administration in a manner that satisfies the specific meal-type and timing limitations of the asserted method patents ('611, '769, and '469).
A key technical question will be one of compositional identity: For the '586 patent, which claims the formulation itself, the case will likely turn on whether Apotex's proposed generic suspension contains the specific combination of ingredients and physical properties (e.g., dispersants, particle size, dissolution rate) recited in the claims.
A final question concerns pharmacokinetic equivalence: Does Apotex's product, when administered as instructed, actually achieve the specific pharmacokinetic outcomes (e.g., Cmax/AUC values comparable to a fasted state or within a certain percentage decrease) required by the '611 and '769 patents? This will likely require a comparison of clinical data from both parties.